Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
85
resultados
Última actualización
15/01/2026 [07:13:00]
Resultados 75 a 85 de 85
Resumen de: WO2024153586A1
The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Resumen de: EP4653454A1
The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.
Resumen de: EP4653011A1
Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.
Resumen de: EP4653459A1
The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.
Resumen de: US2025352517A1
An object is to provide a composition for treatment or prevention of an infection caused by SARS-COV-2 (COVID-19). Based on establishment of a screening method for drugs having an inhibitory activity against proteases of SARS-COV2, and discovery of an inhibitory activity of selenoneine against the proteases of SARS-COV2, a composition for treatment or prevention of COVID-19, which composition includes selenoneine, is provided.
Resumen de: US2025352640A1
The invention is situated in the field of vaccination therapy. More specifically, the invention relates to a multi-epitope construct comprising nucleic acid sequences encoding peptides or functional variants and fragments thereof derived from a coronavirus. The invention further relates to a combination, polypeptides, or pharmaceutical composition for use in the treatment or prevention a coronavirus in a subject; in particular the SARS-COV-2 virus.
Resumen de: US2025352527A1
Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.
Resumen de: WO2025240699A1
Codon-optimized nucleic acids encoding the XBB 1.5 or KP.2 SARS-CoV-2 protein and their use are provided.
Resumen de: US2025352561A1
Compositions and methods for treating any one of the disclosed indications involving inflammation in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition including a tetrahydrocannabinol (THC) constituent. The composition is beneficial in reducing inflammation and/or inhibiting the production of pro-inflammatory cytokines and/or converting inflammatory M1 phenotype macrophages into anti-inflammatory M2 phenotype macrophages. It is useful in treating indications such as COVID-19, PASC/long COVID, effects related to ROSC, exposure to chemical or biological weapons, chemotherapy side effects, graft versus host disease, kidney damage from inflammation, chronic obstructive pulmonary disease, aging, and ARDS resulting from COVID-19, mechanical ventilation, shock, sepsis. In further embodiments, the composition may further include fluvoxamine, melatonin, or other disclosed constituents.
Nº publicación: US2025352558A1 20/11/2025
Solicitante:
SRICHANA TEERAPOL [TH]
SRICHANA Teerapol
Resumen de: US2025352558A1
The present invention relates generally to a method of formulation of cannabidiol (CBD) a potential anti-inflammatory drug derived from lemon peel (d-limonene). More, particularly, the present invention relates to the enhancement of lipid soluble CBD into water soluble form in order to improve the formulation of the active component while apply in human for medication. The present invention further provides the therapeutic application of the new formulation which either neutralize and/or decreases the capability of the production of cytokines by activated immune cells during inflammatory process and hence alleviate the sufferings of illness like COVID-19 caused by SARSCOV2.
BOPI
Sede Electrónica
